Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.

MLA

Synan, Colleen, et al. “Ulotaront, a Novel TAAR1 Agonist with 5-HT1A Agonist Activity, Lacks Abuse Liability and Attenuates Cocaine Cue-Induced Relapse in Rats.” Drug and Alcohol Dependence, vol. 231, Feb. 2022, p. 109261. EBSCOhost, https://doi.org/10.1016/j.drugalcdep.2021.109261.

APA

Synan, C., Bowen, C., Heal, D. J., Froger-Colléaux, C., Beardsley, P. M., Dedic, N., Hopkins, S. C., Campbell, U., & Koblan, K. S. (2022). Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats. Drug and Alcohol Dependence, 231, 109261. https://doi.org/10.1016/j.drugalcdep.2021.109261

Chicago

Synan, Colleen, Carrie Bowen, David J Heal, Christelle Froger-Colléaux, Patrick M Beardsley, Nina Dedic, Seth C Hopkins, Una Campbell, and Kenneth S Koblan. 2022. “Ulotaront, a Novel TAAR1 Agonist with 5-HT1A Agonist Activity, Lacks Abuse Liability and Attenuates Cocaine Cue-Induced Relapse in Rats.” Drug and Alcohol Dependence 231 (February): 109261. doi:10.1016/j.drugalcdep.2021.109261.